Skip to main content
Signal8
Launch Terminal

BECTON DICKINSON & CO (BDX)

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Instruments & Supplies

Becton, Dickinson and Company logo

Becton, Dickinson and Company

NYSE:BDXHealthcare
-0.23%$197.88
AH$197.88+0.00%vs close
Mkt Cap$53.9B
Float274.63M
O/S272.39M
Vol
$ Vol
RVOL
Inst Own95.9%
SI3.2%
Earnings
Div Yield2.01%
Dilution
Becton, Dickinson and Company logoNYSE:BDX$197.88-0.23%
Phase Distribution
61 lead-sponsored trials·4 active·48 completed
Phase 11
Phase 1/23
Phase 23
Not applicable51
Not reported3
(29 more as collaborator)
Status Overview
Not yet recruiting1
Recruiting4
Completed48
Stopped8

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 2
    Completed

    Feasibility Study of the Effect of Intra-Dermal Insulin Injection on Blood Glucose Levels After Eating

    Regular insulin (Humulin), Insulin lispro (Humalog)

    Diabetes Mellitus, Type 1

    Enrollment
    30
    Start
    Sep 2007
    Primary Completion
    Dec 2007
    Completion
    Jan 2008
    NCT00553488
  • Phase 2
    Completed

    Effectiveness of an Antimicrobial Agent for Preoperative Skin Preparation

    OCT - clear, OCT- tinted

    Preoperative Skin Preparation

    Enrollment
    131
    Start
    Jun 2017
    Primary Completion
    Aug 2017
    Completion
    Oct 2017
    NCT03224299
  • Phase 2
    Completed

    Evaluation of the Antimicrobial Effectiveness of an Antimicrobial Cloth

    Octenidine Dihydrocloride in aqueous solution

    Preoperative Skin Preparation

    Enrollment
    99
    Start
    Jun 2017
    Primary Completion
    Aug 2017
    Completion
    Aug 2017
    NCT03229759
  • Phase 1/2
    Completed

    Pharmacokinetics/Dynamics of Basal (Continuous) Insulin Infusion Administered Either Intradermally or Subcutaneously

    Intradermal insulin delivery: BD Research Catheter Set, Subcutaneous insulin delivery:ACCU-CHEK Rapid-D Infusion Set

    Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

    Enrollment
    20
    Start
    Jan 2010
    Primary Completion
    Mar 2010
    Completion
    Mar 2010
    NCT01061216
  • Phase 1/2
    Completed

    Study on the Effects on Blood Glucose Following Intradermal and Subcutaneous Dosing of Insulin in Diabetic Patients

    BD Research Catheter with 34G x 1.5 mm needle, Subcutaneous delivery of insulin using Disetronic Accu-Chek Rapid D infusion set

    Diabetes

    Enrollment
    20
    Start
    Apr 2010
    Primary Completion
    Oct 2010
    Completion
    Oct 2010
    NCT01120444
  • Phase 1/2
    Completed

    Multi-day (3) In-patient Evaluation of Intradermal Versus Subcutaneous Basal and Bolus Insulin Infusion

    Subcutaneous delivery via Medtronic Quick-Set, Intradermal delivery via the BD Research Catheter Set

    Diabetes

    Enrollment
    23
    Start
    Feb 2012
    Primary Completion
    May 2012
    Completion
    May 2012
    NCT01557907
  • Phase 1
    Completed

    A Comparison Study of Prototype Continuous Glucose Sensors in the Intradermal and Subcutaneous Spaces

    BD Continuous glucose monitor (BD CGM), YSI Glucose Analyzer

    Diabetes

    Enrollment
    40
    Start
    Jan 2009
    Primary Completion
    Apr 2009
    Completion
    Apr 2009
    NCT01093833
  • Not applicable
    Completed

    Evaluation of Blood Volume and Perceived Pain During Fingerstick Monitoring of Blood Glucose

    BD/33G, OTM / 33G

    Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

    Enrollment
    250
    Start
    Aug 2008
    Primary Completion
    Sep 2008
    Completion
    Sep 2008
    NCT00741390
  • Not applicable
    Completed

    Comparison of Glycemic Control Among Diabetics Using Three Different Pen Needles

    4mm x 32G pen needle, 8mm x 31G pen needle

    Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

    Enrollment
    173
    Start
    Jun 2009
    Primary Completion
    Nov 2009
    Completion
    Nov 2009
    NCT00928057
  • Not applicable
    Completed

    Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles

    4 mm x 32G Pen Needle, 8mm x 31G Pen Needle

    Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

    Enrollment
    293
    Start
    Oct 2010
    Primary Completion
    May 2012
    Completion
    May 2012
    NCT01231984
  • Not applicable
    Terminated

    Evaluation of a 4mmx32G Pen Needle for Injection of Basal Insulin Doses Above 40 Units

    4 mm x 32G pen needle (Nano), 8mm x 31G pen needle (Short)

    Diabetes Mellitus, Type 2

    Enrollment
    21
    Start
    Mar 2011
    Primary Completion
    Jun 2011
    Completion
    Jun 2011
    NCT01334606
  • Not applicable
    Completed

    Three-day, In-clinic Evaluation of the BD 2nd Generation Continuous Glucose Sensor Device in Type 1 Diabetics

    BD CGM with Outer Layer, BD CGM without Outer Layer

    Diabetes

    Enrollment
    30
    Start
    Jun 2012
    Primary Completion
    Sep 2012
    Completion
    Sep 2012
    NCT01645696
  • Observational
    Completed

    European Clinical Evaluation of the BD HPV Assay on the BD Viper LT System

    BD HPV assay on Viper LT

    Uterine Cervical Neoplasms

    Enrollment
    1,365
    Start
    Aug 2012
    Primary Completion
    Nov 2013
    Completion
    Nov 2013
    NCT01671462
  • Not applicable
    Completed

    Study of Effectiveness of Smaller Gauge Fenestrated Catheters for Use in IV Contrast Enhanced CT Scans

    20GA BD Nexiva Diffusics, 18GA Conventional Catheter

    Contrast Enhanced Computed Tomography

    Enrollment
    238
    Start
    Jan 2013
    Primary Completion
    Feb 2013
    Completion
    Feb 2013
    NCT01772550
  • Observational
    Completed

    Clinical Evaluation of BD NEXT Pen Needle

    BD NEXT 31G x 5 mm pen needle, BD NEXT 31G x 8mm pen needle

    Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1

    Enrollment
    217
    Start
    Sep 2012
    Primary Completion
    Dec 2012
    Completion
    Dec 2012
    NCT01852136
  • Not applicable
    Completed

    Clinical Evaluation of the BD Onclarity™ HPV Assay on the BD Viper™ LT System With Cervical Specimens

    BD Onclarity™ HPV assay on BD Viper™ LT, Colposcopy

    Uterine Cervical Neoplasms

    Enrollment
    33,858
    Start
    Aug 2013
    Primary Completion
    Mar 2016
    Completion
    Mar 2016
    NCT01944722
  • Observational
    Completed

    Longitudinal Clinical Evaluation of the HPV Assay on the BD VIPER LT System With Cervical Specimens

    BD HPV Assay on Viper LT, Colposcopy

    Cervical Neoplasms, Human Papillomavirus

    Enrollment
    6,730
    Start
    Oct 2014
    Primary Completion
    Dec 2018
    Completion
    May 2019
    NCT02267876
  • Not applicable
    Terminated

    Treating Diabetic Lipohypertrophy With Intensive Education Versus Standard Care

    Intensive Training on Best Insulin Injection Technique, Standard education on injection technique

    Insulin Injections and Lipohypertrophy

    Enrollment
    31
    Start
    Jan 2015
    Primary Completion
    Aug 2016
    Completion
    Dec 2016
    NCT02271594
  • Observational
    Completed

    Monitoring the Infusion Pressure in Insulin Infusion Sets in Healthy Adults

    BD Scarlett Infusion set, Medtronic QuickSet Infusion Set

    Diabetes

    Enrollment
    60
    Start
    Aug 2014
    Primary Completion
    Aug 2014
    Completion
    Aug 2014
    NCT02382536
  • Observational
    Completed

    Accuracy Evaluation of the BD FACS Presto System

    Investigational BD FACSPresto System, BD FACSCalibur flow cytometer

    Acquired Immunodeficiency Syndrome

    Enrollment
    583
    Start
    Feb 2015
    Primary Completion
    May 2015
    Completion
    May 2015
    NCT02396355
  • Observational
    Completed

    BD FlowSmart™ Subcutaneous Insulin Infusion Set User Preference and Claims Study

    FlowSmart Infusion Set, Current Infusion Set

    Type 1 Diabetes Mellitus

    Enrollment
    75
    Start
    Jan 2016
    Primary Completion
    Feb 2016
    Completion
    Feb 2016
    NCT02662842
  • Not applicable
    Terminated

    Validation of BD Onclarity™ HPV Assay With PreservCyt® -ASCUS Samples

    Colposcopy/biopsy

    Uterine Cervical Neoplasm

    Enrollment
    28
    Start
    Nov 2016
    Primary Completion
    May 2017
    Completion
    May 2017
    NCT03020121
  • Not applicable
    Withdrawn

    The PSIQS Study - User Experience With Pro-Set

    MiniMed® Pro-set®, MiniMed® Quick-set®

    Diabetes Mellitus, Type 1

    Enrollment
    0
    Start
    Sep 2017est.
    Primary Completion
    Dec 2017est.
    Completion
    Feb 2018est.
    NCT03242005
  • Not applicable
    Completed

    Evaluating the User Performance and Experience of Nucleus Pen vs. Commercially Available Pen Needle

    BD Nano™ vs Nucleus, NovoFine® vs Nucleus

    Diabetes

    Enrollment
    248
    Start
    Sep 2017
    Primary Completion
    Apr 2018
    Completion
    May 2018
    NCT03267264
  • Not applicable
    Completed

    Comparative User Experiences With BD Nano™ PRO 32G Extra Thin Wall Pen Needle vs the Terumo Nanopass® 34G Pen Needle

    Terumo Nanopass® 34G pen needle, BD Nano™ PRO 32G pen needle

    Diabetes

    Enrollment
    55
    Start
    Feb 2019
    Primary Completion
    Jun 2019
    Completion
    Jun 2019
    NCT03878745

1-25 of 61

Search ClinicalTrials.gov for “Becton Dickinson”